What Are the GCP Requirements for Running Clinical Trials in China as a Foreign Sponsor?

A comprehensive guide to Good Clinical Practice compliance for foreign biotech companies sponsoring clinical trials in China.

Introduction

For foreign biotech companies planning to conduct clinical trials in China, understanding and complying with China’s Good Clinical Practice (GCP) requirements is essential for successful trial execution and subsequent NMPA drug registration. China’s GCP standards have undergone significant evolution since 2020, when the NMPA released a comprehensively revised GCP guideline that aligns closely with ICH E6 (R2) while incorporating China-specific requirements. This article provides a detailed examination of the GCP requirements for foreign sponsors in China, covering the regulatory framework, ethics committee approval processes, investigator qualifications, clinical trial site management, data integrity standards, pharmacovigilance obligations, and practical compliance strategies for foreign biotech companies in 2025–2026.

The Regulatory Framework: China GCP and Its Alignment with ICH E6 (R2)

China’s current GCP framework is primarily governed by the Provisions for Drug Clinical Trial Management (NMPA Order No. 57, effective July 1, 2020), which replaced the 2003 GCP guidelines. This landmark regulation brought China’s GCP standards into substantial alignment with ICH E6 (R2) while adding several China-specific provisions. Key regulatory instruments include:

• Drug Administration Law (2019 revision): Establishes the legal foundation for clinical trial regulation, including sponsor obligations, investigator responsibilities, and subject protection requirements.
• Provisions for Drug Clinical Trial Management (Order No. 57, 2020): The primary GCP regulation covering all aspects of clinical trial conduct, monitoring, auditing, inspection, and record-keeping.
• Guidelines for Quality Management of Clinical Trials (2021): Detailed guidance on trial quality management systems, risk-based monitoring, and centralized statistical monitoring.
• NMPA GCP Inspection Guidelines (2022): Standards for GCP inspections conducted by the NMPA Center for Food and Drug Inspection (CFDI).

Sponsor Responsibilities Under China GCP

As a foreign sponsor, you are ultimately responsible for the conduct, quality, and integrity of clinical trials in China. Key sponsor obligations include:

• Legal presence in China: Foreign sponsors must designate a legal representative or agent in China who can bear legal responsibility for the clinical trial. This is typically a China-based representative office, a subsidiary WFOE, or a contracted CRO with legal standing in China.
• Clinical trial insurance: Sponsors must obtain clinical trial liability insurance before trial initiation and provide financial coverage for trial-related injuries. The insurance policy must be issued by an insurance company licensed to operate in China.
• Trial initiation approval: Obtain IND approval from CDE (60 working days silent approval or explicit approval). The CDE’s IND approval is a prerequisite for ethics committee submission.
• Qualified investigator selection: Select investigators who are qualified by education, training, and experience, and who have access to adequate facilities and patient populations.
• Monitoring and quality assurance: Appoint qualified monitors, conduct regular site visits, and maintain a quality assurance system covering all aspects of trial conduct.
• Safety reporting: Establish a pharmacovigilance system for timely reporting of serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs), and other safety findings to the NMPA and ethics committees.
• Record retention: Maintain essential documents for at least 5 years after the drug’s marketing approval in China, or 2 years after trial discontinuation if no marketing application is filed.

Ethics Committee (EC) Approval Process

Every clinical trial site in China must obtain ethics committee (EC) approval before enrolling subjects. China’s EC system has several distinctive features:

• Institutional ethics committees: Each trial site has its own institutional EC that reviews protocols specific to that site. While the CDE has promoted the concept of a centralized EC review system, in practice, most trials still require separate EC submissions at each participating site.
• EC composition and standards: ECs must include at least 5 members with diverse backgrounds including medical, scientific, legal, and non-scientific (lay) members. ECs operate under the Guidelines for Ethics Committee Review of Drug Clinical Trials (2020) and must be registered with the NMPA.
• Review timeline: EC review takes 30–60 days typically, depending on the complexity of the protocol and the schedule of EC meetings.
• Required documents for EC submission: Clinical trial protocol and amendments, investigator’s brochure (IB), informed consent form (ICF) in Chinese, case report forms (CRFs), investigator qualifications and curriculum vitae, subject recruitment materials, clinical trial insurance certificate, CDE IND approval letter, and compensation and treatment arrangements for trial-related injuries.
• Ongoing EC oversight: ECs require annual progress reports, immediate reporting of SAEs and protocol deviations, and final trial completion reports. EC approval must be renewed annually for trials lasting more than one year.

Investigator Qualifications and Responsibilities

China GCP imposes specific requirements on clinical trial investigators that foreign sponsors must verify:

• Qualification requirements: Investigators must be licensed physicians with relevant specialty training, have at least 3 years of clinical trial experience or equivalent training, and have completed NMPA-recognized GCP training (which must be renewed every 3 years).
• Site facilities: Trial sites must have adequate facilities including appropriately equipped examination rooms, clinical laboratories with valid certifications, emergency equipment and medications, and secure document storage.
• Staffing requirements: Principal investigators must dedicate sufficient time to the trial and must have qualified sub-investigators and study coordinators. China does not have a formal clinical research coordinator (CRC) certification system, but CRC competence must be documented.
• Subject enrollment obligations: Investigators must not delegate subject recruitment, informed consent, or medical decision-making to non-physicians. Informed consent must be obtained in person by the investigator or a qualified sub-investigator.
• Data recording and reporting: All trial data must be recorded in source documents and CRFs promptly, accurately, and completely. Corrections must be made as a new entry (with date, reason, and signature) — no erasures or overwriting.

Informed Consent Requirements

Informed consent in China has specific requirements that foreign sponsors must carefully observe:

• Language: The ICF and subject information sheet must be written in simplified Chinese at a reading level appropriate for the target subject population. Translations must be certified.
• Content requirements: Beyond standard ICH E6 elements, China GCP requires specific content including: the experimental nature of the trial, expected duration and number of subjects, alternative treatments available in China, compensation arrangements, insurance details, data privacy and confidentiality provisions, and contact information for the EC and sponsor’s China representative.
• Vulnerable populations: Additional protections apply for minors, pregnant women, cognitively impaired subjects, critically ill patients, and economically disadvantaged subjects. For minors, consent must be obtained from both parents or legal guardians, and assent from the minor where appropriate based on age and capacity.
• Informed consent process documentation: The consent discussion must be documented with date, time, and signature of both subject and investigator. A copy of the signed ICF must be provided to the subject.
• Re-consent: Subjects must be re-consented when new safety information emerges, when the protocol is amended, or when significant new findings become available during the trial.

Data Management and Integrity

China GCP has specific requirements for clinical trial data management that foreign sponsors must comply with:

• Electronic data capture (EDC): EDC systems used in Chinese clinical trials must comply with China’s GCP requirements for electronic records and signatures. The system must have audit trails, user authentication, data validation checks, and backup procedures.
• Source data verification (SDV): Monitors must perform SDV for all primary efficacy and safety endpoints, and for a statistically justified sample of secondary endpoints. 100% SDV is typically required for regulatory submission-ready trials.
• Data localization: Clinical trial data generated in China must be stored on servers physically located within mainland China. Cross-border data transfer is regulated by the Personal Information Protection Law (PIPL), the Data Security Law (DSL), and the Human Genetic Resources (HGR) regulations.
• Human genetic resources (HGR) compliance: Before any Chinese clinical trial biospecimens can be exported or shared with international research teams, the sponsor must obtain approval from the Ministry of Science and Technology (MOST) under the HGR regulations. The approval process typically takes 3–6 months and must be initiated before trial enrollment begins.
• Quality by design (QbD): The CDE encourages a QbD approach to clinical trial quality management, including prospective risk assessment, critical-to-quality factor identification, and risk-based monitoring.

Safety Reporting and Pharmacovigilance

China’s safety reporting requirements under GCP are detailed and timeline-driven:

• Serious adverse events (SAEs): Must be reported to the NMPA and ethics committees within 7 calendar days for fatal or life-threatening SAEs, and within 15 calendar days for other SAEs.
• Suspected unexpected serious adverse reactions (SUSARs): Expedited reporting of SUSARs is required within 7 days for fatal/life-threatening and 15 days for others (same as SAEs).
• Development Safety Update Reports (DSURs): Annual DSURs must be submitted to the NMPA for each ongoing clinical trial.
• Local pharmacovigilance system: Foreign sponsors must establish a China-based pharmacovigilance system with a qualified person responsible for safety reporting. This can be through a local affiliate, a designated agent, or a contracted CRO with pharmacovigilance capabilities.
• NMPA safety database integration: The sponsor’s safety database must be capable of submitting reports to the NMPA’s adverse drug reaction monitoring system in the required format.

NMPA GCP Inspections: What Foreign Sponsors Should Expect

The NMPA’s Center for Food and Drug Inspection (CFDI) conducts GCP inspections to verify compliance with clinical trial regulations. Foreign sponsors should be prepared for:

• Inspection triggers: Routine inspections (random selection of ongoing or completed trials), for-cause inspections (triggered by safety concerns, data integrity questions, or complaints), and registration inspections (for trials supporting NDA applications).
• Inspection scope: Inspectors review investigator qualifications, facilities, informed consent processes, subject records, drug accountability, SAE reporting, data integrity, and overall GCP compliance.
• Inspection outcomes: Findings are classified as critical (data integrity or subject safety compromised), major (significant GCP non-compliance), or minor (administrative issues). Critical and major findings can result in inspection failure, leading to data rejection for NDA purposes.
• Remote inspections: Following the pandemic, the CFDI has adopted remote inspection capabilities for reviewing documents and records, though on-site inspections remain the primary method for complex trials.

Common Compliance Challenges and Best Practices

Foreign sponsors frequently encounter the following GCP compliance challenges in China:

• Language and translation quality: Protocols, ICFs, and other documents must be accurately translated into Chinese. Poor translation can lead to misunderstandings, protocol deviations, and regulatory findings. Engage certified medical translators with clinical trial experience.
• Cultural differences in informed consent: Chinese subjects may be less likely to ask questions or refuse participation due to cultural deference to physicians. Investigators should be trained to actively verify subject understanding during the consent process.
• Site monitoring challenges: China’s geographic vastness makes site monitoring resource-intensive. Use risk-based monitoring strategies and consider centralized monitoring for low-risk sites.
• HGR approval delays: The MOST HGR approval process is often underestimated. Begin the HGR application at least 3 months before the first subject enrollment.
• Data localization costs: Maintaining China-based data servers and ensuring PIPL/DSL compliance adds costs that should be budgeted from the start of trial planning.

Conclusion

China GCP requirements for foreign sponsors are comprehensive and closely aligned with ICH E6 (R2) standards, while incorporating important China-specific provisions covering ethics committee processes, HGR compliance, data localization, informed consent requirements, and pharmacovigilance obligations. Successful GCP compliance in China requires early engagement with the CDE, careful selection of qualified investigators and trial sites, establishment of robust China-based quality management and pharmacovigilance systems, and diligent attention to the unique regulatory and cultural aspects of conducting clinical trials in China. For foreign biotech companies that invest the time and resources to understand and comply with these requirements, China offers one of the world’s most efficient clinical trial environments, with rapid patient enrollment, high-quality investigators, and reliable regulatory timelines.

This article is for informational purposes only and does not constitute legal or regulatory advice. GCP requirements are based on current NMPA regulations as of 2025–2026 and may be subject to change. Foreign sponsors should consult qualified clinical operations and regulatory affairs professionals for guidance on their specific clinical trial programs.